A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Clinical trial NCT03690388 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03690388
- Sponsor
- Exelixis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-05
- Primary completion
- 2020-08-19
- Enrollment
- 187
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.